Trial Profile
Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DOPAD
- 15 Jul 2020 Results published in the Media Release
- 15 Jul 2020 According to Alzheimers Drug Discovery Foundation media release, data from this trial was published in JAMA Network Open. Study is Funded by the Alzheimer's Drug Discovery Foundation.
- 14 Dec 2018 Status changed to completed.